Shots:

• Boston has entered into a definitive agreement to acquire Baylis for $1.75B up front. The transaction is anticipated to close in Q1’22
• The acquisition will bolster Boston’s electrophysiology and structural heart product portfolios with the addition of Baylis’ platforms i.e.- NRG and VersaCross Transseptal that uses radiofrequency to access the left side of the heart
• The platforms are designed for use in left-sided diagnostic- ablation- mitral- and LAAC procedures. Baylis has received US FDA’s 510(k) clearance for the NRG & VersaCross platform in 2008 & 2020 respectively

  | Ref: Boston Scientific | Image: Star Tribune